Multiplex Assay Kit for Galectin 9 (GAL9) ,etc. by CBA (Cytometric Bead Array)
LGALS9; Ecalectin; Lectin,Galactoside-Binding Soluble 9; Tumor antigen HOM-HD-21
Overview
Properties
- Product No.CMA309Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryInfection immunity
Sign into your account
Share a new citation as an author
Upload your experimental result
Review

Contact us
Please fill in the blank.
Recovery
Matrices listed below were spiked with certain level of recombinant Galectin 9 (GAL9) ,etc. by CBA (Cytometric Bead Array) and the recovery rates were calculated by comparing the measured value to the expected amount of Galectin 9 (GAL9) ,etc. by CBA (Cytometric Bead Array) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 83-97 | 91 |
| EDTA plasma(n=5) | 80-99 | 95 |
| heparin plasma(n=5) | 89-96 | 93 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Galectin 9 (GAL9) ,etc. by CBA (Cytometric Bead Array) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Galectin 9 (GAL9) ,etc. by CBA (Cytometric Bead Array) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Galectin 9 (GAL9) ,etc. by CBA (Cytometric Bead Array) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 93-101% | 98-105% | 96-104% | 96-105% |
| EDTA plasma(n=5) | 80-91% | 79-105% | 80-99% | 91-101% |
| heparin plasma(n=5) | 94-102% | 78-101% | 98-105% | 95-105% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
Assay procedure summary
1. Add 200μL analysis buffer solution to each well of the plate for pre-wetting;
2. Preparation of standards, reagents and samples before the experiment;
3. Add 100μL standard or sample to each well, add 10μL magnetic beads, and incubate 120 minutes protect from light at 25°C on shaker;
4. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60 minutes protect from light at 25°C on shaker;
5. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent B, and incubate 30 minutes protect from light at 25°C on shaker;
6. Wash plate once on magnetic frame;
7. Add 100μL sheath fluid, swirl for 10 minutes, read on the machine.
Test principle
Anti-Galectin 9 (GAL9) ,etc. by CBA (Cytometric Bead Array) antibody was coated on the surface of magnetic beads, to make solid phase carrier. Standard or sample were added to the magnetic beads, respectively, in which Galectin 9 (GAL9) ,etc. by CBA (Cytometric Bead Array) was bound to the antibody connected to the solid phase carrier, and then biotinylated anti-Galectin 9 (GAL9) ,etc. by CBA (Cytometric Bead Array) antibodies were added. PE-labeled avidin was added. There is a positive correlation between the concentration of Galectin 9 (GAL9) ,etc. by CBA (Cytometric Bead Array) in the sample and corresponding value of MFI (Median Fluorescence Intensity). Flow Cytometer was used to determine and calculate the sample concentration.
Giveaways
Increment services
Citations
- Temporal Increases in Urinary Carboxymethyllysine Correlate with Albuminuria Development in DiabetesKarger: 328581
- Galectin-9 administration ameliorates CVB3 induced myocarditis by promoting the proliferation of regulatory T cells and alternatively activated Th2 cellsScienceDirect: S1521661611001057
- Rat Renal Interstitial Fibroblasts Affect the Th1/Th2 Profile In VitroPubmed: 22013937
- Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney diseasePubMed: 23339460
- Dysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infectionPubMed: PMC3750478
- Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus InfectionPubMed: PMC3480425
- Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis CPubMed: PMC3688567
- Graves’ Disease Is Associated with a Defective Expression of the Immune Regulatory Molecule Galectin-9 in Antigen-Presenting Dendritic CellsPubMed: 25880730
- Molecules of Damage-Associated Patterns in Bronchoalveolar Lavage Fluid and Serum in Chronic Obstructive Pulmonary DiseasePubmed:29429028
- Galectin-9-like from Angiostrongylus cantonensis young adult worms modulates eosinophil chemotaxis in vitroDoi: 10.1016/j.jmii.2018.09.010
- The effects of Tim‑3 activation on T‑cells in gastric cancer progression
- Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra …Pubmed: 31337865
- Blood Levels of Galectin-9, an Immuno-Regulating Molecule, Reflects the Severity for the Acute and Chronic Infectious Diseases. Biomolecules 2021, 11, 43033804076
- Regulatory T cells, damage-associated molecular patterns, and myeloid-derived suppressor cells in bronchoalveolar lavage fluid interlinked with chronic obstructive …Pubmed:35687771
